Flerlage JE, Eichenauer DA, Fuchs M, Hartmann S, Eich HT, Savage KJ, Lo AC, Skinnider B, Akhtar S, Rauf MS, Maghfoor I, Pinnix CC, Steiner R, Milgrom SA, Vega F, Alomari M, Zhang XY, Collins GP, Advani RH, Kumar P, Dickinson M, Wirth A, Tsang R, Prica A, Major A, Smith S, Hendrickson PG, Kelsey CR, Hopkins D, McKay P, Ng A, Koenig J, Constine LS, Casulo C, Sakthivel G, Baron J, Plastaras JP, Roberts KB, Gao S, Al Kendi J, Al Rahbi N, Balogh A, Levis M, Ricardi U, Sridhar A, Torka P, Specht L, De Silva R, Shah N, Pickard K, Osborne W, Blazin LJ, Henry M, Chang I, Smith CM, Halperin D, Miall F, Brady JL, Mikhaeel G, Brennan B, Penn A, Senchenko MA, Volchkov EV, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Della Pepa R, Picardi M, Kirova Y, Fergusson P, Northend M, Hawkes E, Lee D, Doo NW, Barraclough A, Opat S, Cheah CY, Salvaris R, Ku M, Hamad N, Mutsando H, Tedjaseputra A, Gilbertson M, Marconi T, Viiala N, Palese M, Shankar A, Maurer MJ, Natkunam Y, Kelly KM, Borchmann P, Hoppe RT, Binkley MS. Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses. Blood Adv. 2026 Aug 11; 10(15):5338-5347.

Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.

Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257.

Griesinger AM, Widener M, Donson AM, Mettetal A, Hankinson TC, Handler M, Mulcahy Levy JM, Lindsay HB, Macy ME, Foreman NK, Dorris K. Molecular biology and phase 1 study of GM-CSF and intrathecal trastuzumab in children with recurrent -posterior fossa ependymoma. Neuro Oncol. 2026 Jul 01; 28(7):1783-1793.

Vogel A, Ben Khaled N, Ramirez JR, Marhenke S, Siegler G, Siebler J, Lindig U, Schwartz G, Schultheiss M, Mueller T, Simon H, De Toni EN, Karl D, Al-Batran SE, Saborowski A. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. Eur J Cancer. 2026 Jul 26; 243:116847.

Pollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt VR, Fathi AT, Fedorov K, Foran JM, Gojo I, Goldberg A, Hall AC, Jonas BA, Levine MR, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival ME, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone RM, Thota S, Uy GL, Walker A, Wang E, Awotiwon A, Roth SL, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. J Natl Compr Canc Netw. 2026 Jun; 24(6):222-229.

Rosenberg JE, O'Donnell PH, Petrylak DP, Flaig TW, Hoimes CJ, Gupta S, Mar N, Friedlander TW, Tagawa ST, Bilen MA, Brown JR, McKay RR, Merchan JR, Srinivas S, Gorla S, Moreno BH, Davis G, Wirtz HS, Zhu Y, Milowsky MI. EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. ESMO Open. 2026 Jun; 11(6):107700.

Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J. Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. J Clin Oncol. 2026 06 20; 44(18):1697-1708.

Smith AA, Onar-Thomas A, Lensing S, Dalton J, Bennett J, Tatevossian RG, Bertrand K, Lindsay H, Tabori U, Owens-Pickle E, Blackburn PR, Handler MH, Chambwe N, El Khoury L, Lau C, Kunin-Batson A, Sands S, Wu S, Zhou T, Chang A, Merchant TE, Leary S, Fouladi M, Gajjar A, Pollack IF, Foreman NK, Ellison DW. Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group. Neuro Oncol. 2026 May 01; 28(5):1286-1297.

Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L. Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. J Clin Oncol. 2026 Jul; 44(19):1767-1773.